Singh brothers on the hook for $525M over Ranbaxy sale to Daiichi.

Sales of Regeneron hotshot Eylea will still slow down in 2016--but not as drastically as the company initially expected.

One analyst called Merck & Co.’s new product sales for the first quarter “uninspiring.” The same could be said of the entire Q1 report, with every gain for…

Sanofi CEO Olivier Brandicourt says he just might sweeten his $9.3 billion Medivation bid, provided execs sit down for talks. If they don't? Sanofi will…

Bayer has pegged cancer drug Stivarga as one of 5 drugs that’ll drive its future growth. And now, it has some new data in hand that could help it do just that.

An early recommendation for a trial waiver for Sanofi's dengue vaccine Dengvaxia in India was shot down by a health ministry review panel.

India faces flak from civil society groups if it moves away from domestic policies that are friendly to generic drug manufacture in a proposed regional trade…

Turing outraged the public with its notorious 5,000% price hike on Daraprim. Ex-CEO Martin Shkreli's pharma “bad bro” image is as well-known as any…

The world’s first gene therapy may be teaching pharma an important lesson: There’s a ceiling on drug prices, even for outright cures, unless and until pharma…